This is a translation of the original article in Portuguese. Read the original (Português).
Brazil’s National Supplementary Health Agency (ANS) has added next-generation sequencing and the oral drug tepotinib hydrochloride, used to treat lung cancer, to the mandatory coverage list for health plans. The information comes from the Brazilian newspaper Correio da Manhã, Distrito Federal edition.
The resolution was published in the Official Gazette of the Union on November 16. The new coverage, however, will only take effect in February 2027, giving health plan operators time to adapt.
Next-generation sequencing is a genetic test that analyzes tumor material. In general terms, it helps identify alterations that can guide the choice of treatment. Tepotinib, in turn, is a medication taken orally, that is, in pill form, without the need for administration in a hospital or clinic.
What changes for patients
For those with health plans, including these items on the list means the test and the drug become part of the procedures that operators are required to provide. In practice, beneficiaries will no longer need a court order to obtain coverage, a path many patients must take when a treatment is not yet on the list.
Until February 2027, the rule does not yet apply. From that date on, coverage must be requested from the plan with the referral of the physician responsible for the case. Details on how operators will organize care and the criteria for authorizing the test and the drug are still to be defined by the ANS and the companies.
Lung cancer is among the types of the disease with the highest fatality rates, and access to accurate diagnosis and more modern therapies is often one of the main obstacles faced by patients.
The rule has nationwide reach and applies to health plans regulated by the agency, regardless of the state where the beneficiary lives.
Reporting from Correio da Manhã Edição Distrito Federal (p. 12, edição impressa).
Deixe um comentário